GE Healthcare

healthymagination

Investor Update

Exhibit (a)(5)(d)

"Results

are

preliminary

and

unaudited.

This

document

contains

“forward-looking

statements”-

that

is,

statements

related

to

future,

not

past,

events.

In

this

context,

forward-looking

statements

often

address

our

expected

future

business

and

financial

performance

and

financial

condition,

and

often

contain

words

such

as

“expect,”

“anticipate,”

“intend,”

“plan,”

“believe,”

“seek,”

“see,”

or

“will.”

Forward-looking

statements

by

their

nature

address

matters

that

are,

to

different

degrees,

uncertain.

For

us,

particular

uncertainties

that

could

cause

our

actual

results

to

be

materially

different

than

those

expressed

in

our

forward-looking

statements

include:

current

economic

and

financial

conditions,

including

volatility

in

interest

and

exchange

rates,

commodity

and

equity

prices

and

the

value

of

financial

assets;

the

impact

of

conditions

in

the

financial

and

credit

markets

on

the

availability

and

cost

of

General

Electric

Capital

Corporation’s

(GECC)

funding

and

on

our

ability

to

reduce

GECC’s

asset

levels

as

planned;

the

impact

of

conditions

in

the

housing

market

and

unemployment

rates

on

the

level

of

commercial

and

consumer

credit

defaults;

changes

in

Japanese

consumer

behavior

that

may

affect

our

estimates

of

liability

for

Grey

Zone

claims;

our

ability

to

maintain

our

current

credit

rating

and

the

impact

on

our

funding

costs

and

competitive

position

if

we

do

not

do

so;

the

adequacy

of

our

cash

flow

and

earnings

and

other

conditions

which

may

affect

our

ability

to

pay

our

quarterly

dividend

at

the

planned

level;

the

level

of

demand

and

financial

performance

of

the

major

industries

we

serve,

including,

without

limitation,

air

and

rail

transportation,

energy

generation,

network

television,

real

estate

and

healthcare;

the

impact

of

regulation

and

regulatory,

investigative

and

legal

proceedings

and

legal

compliance

risks,

including

the

impact

of

financial

services

regulation;

strategic

actions,

including

acquisitions

and

dispositions

and

our

success

in

integrating

acquired

businesses;

and

numerous

other

matters

of

national,

regional

and

global

scale,

including

those

of

a

political,

economic,

business

and

competitive

nature.

These

uncertainties

may

cause

our

actual

future

results

to

be

materially

different

than

those

expressed

in

our

forward-looking

statements.

We

do

not

undertake

to

update

our

forward-looking

statements.”

“This

document

may

also

contain

non-GAAP

financial

information.

Management

uses

this

information

in

its

internal

analysis

of

results

and

believes

that

this

information

may

be

informative

to

investors

in

gauging

the

quality

of

our

financial

performance,

identifying

trends

in

our

results

and

providing

meaningful

period-to-period

comparisons.

For

a

reconciliation

of

non-GAAP

measures

presented

in

this

document,

see

the

accompanying

supplemental

information

posted

to

the

investor

relations

section

of

our

website

at

www.ge.com.”

“Effective

January

1,

2010,

we

reorganized

our

segments.

We

have

reclassified

prior-period

amounts

to

conform

to

the

current-period’s

presentation.”

“In

this

document,

“GE”

refers

to

the

Industrial

businesses

of

the

Company

including

GECS

on

an

equity

basis.

“GE

(ex.

GECS)”

and/or

“Industrial”

refer

to

GE

excluding

Financial

Services.”

Precise therapy

requires precise

diagnostics

The way we look at disease is changing

Assembling the necessary technologies

to lead

Responders

Patient populations

Investing in molecular diagnostics

Mammography

Molecular Biopsy Tools

Tumor

+

IHC Stain

Gene sequencing

Molecular pathology

Imaging

Molecular Diagnostics

Operations &

commercialization

Molecular imaging

agents & equipment

Technology &

content

Enabling

workflow

in vivo

diagnostics

GRC

Molecular

Pathology

Digital

Pathology

Clarient

1

Macro

Trend

Molecular profiling segment for cancer expected to

grow from $15B in 2009 to $47B in 2015

... to be a leader in the next diagnostic

frontier

Toxic

impact

No

impact 

Investing in molecular

diagnostics

Pascale

Witz

President and CEO,

GEHC, Medical Diagnostics 

Clarient disclaimer:

Forward Looking Statements 

Certain statements in this presentation regarding Clarient, Inc. and General Electric Company and the proposed transaction contain

forward-looking statements that involve risks and uncertainty. Future events regarding the proposed transaction and both Clarient's

and GE’s actual results could differ materially from the forward-looking statements. Factors that might cause such a difference

include, but are not limited to: delays in completing, or the failure to complete, the proposed transaction due to a failure to satisfy

closing conditions or other reasons, Clarient's ability to continue to develop and expand its diagnostic services business,

uncertainties inherent in Clarient's product development programs, Clarient's ability to attract and retain highly qualified managerial,

technical, and sales and marketing personnel, uncertainty of success in identifying, developing and commercializing new diagnostic

tests or novel markers including the Mammostrat(R) test, Clarient's ability to fund development of new diagnostic tests and novel

markers, and to obtain adequate patent protection covering Clarient's use of these tests and markers including for the

Mammostrat(R) test, and the amount of resources Clarient determines to apply to novel marker development and commercialization,

the risk to Clarient of infringement claims and the possibility of the need to license intellectual property from third parties to avoid or

settle such claims, failure to obtain regulatory approvals and clearances required to conduct clinical trials if/when required and/or to

commercialize Clarient's services and underlying diagnostic applications, Clarient's ability to compete with other technologies and

with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests,

and risks detailed from time to time in Clarient's and GE’s reports filed with the U.S. Securities and Exchange Commission (“SEC”),

including quarterly reports on Form 10-Q, current reports on Form 8-K, and annual reports on Form 10-K. Recent experience with

respect to laboratory services, net revenues and results of operations may not be indicative of future results for the reasons set forth

above. Neither Clarient nor GE assumes any obligation to update any forward-looking statements or other information contained in

this document.  

Important Additional Information

This presentation is neither an offer to purchase nor a solicitation of an offer to sell any securities. In connection with the proposed

transaction, General Electric Company and Crane Merger Sub, Inc. have filed tender offer documents with the SEC. These

documents have been mailed to all Clarient stockholders of record. These documents, as they may be amended from time to time,

contain important information about the proposed transaction and Clarient stockholders are urged to read them carefully and in their

entirety before any decision is made with respect to the proposed transaction. The tender offer materials may be obtained at no

charge by directing a request by mail to Morrow & Co., LLC, 470 West Avenue – 3rd Floor, Stamford, CT  06902, or by calling toll-

free at (800) 279-6413, and may also be obtained at no charge at the website maintained by the SEC at www.sec.gov. 

$1.8B

2009

Q3’10 YTD V (3)%

Revenues

2015+

~8%

CAGR

Expand contrast media to developing markets

Launch Parkinson’s and cardiology imaging agents

in new markets

Deliver PET/in vivo molecular imaging pipeline

Establish leadership in molecular diagnostics

Key strategies

2011 market

Contrast Media mature in developed markets

Growth opportunities in developing markets

New Molecular Imaging agents growing strongly

(DaTSCAN

†

, 17%; AdreView, 13%)

Opportunity for MDx

†DaTSCAN

not  approved by U.S. FDA; currently at FDA for review

The way we look at cancer is evolving

Mammography

Tumor

•

Tumor stage

•

Favorable vs. Unfavorable

•

HER2, Hormone Receptor

•

Gene mutations: BRCA1, BRCA2

•

Breast cancer

Organ

Stage/

Structure

Molecular

profile

http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/breast-cancer-treating-hormone-therapy

http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/breast-cancer-treating-targeted-therapy`

•

Tumor molecular profile determines

treatment and prognosis

•

The right therapy for the right patient

•

Overall healthcare system costs

reduced …

increased efficiency

Therapies above have targeted

effectiveness

Femara™

Pharma’s

transition to bio-therapeutics

Bio-therapeutics address big unmet needs

Targeted drugs need powerful diagnostics

In vitro molecular

diagnostics brings

advantages in

access, development

time and cost

Combination will allow

more complete

disease management

Imaging required to

localize disease

Broader GEHC diagnostic offering

In vivo

Imaging

Dx

Example …

breast cancer care

250,000+ new breast cancer diagnoses in the US per annum

Confirm Dx

& Rx

selection

Screening

Diagnostic

workup

Treatment

monitoring

Mammo

$3.1B

38M screened

Mammo

U/S

MR

>$500M

3M exams

Biopsy

$250M

1.2M procedures

>$100M

>35k tests

Prognostics

in vitro

IVD screening

to lower

mammo

recall rate

in vivo

Imaging procedures

to  reduce

unnecessary

biopsies

in vitro

Molecular pathology

to help

choose the best

therapy

in vivo

Imaging agents to

monitor  therapy

effectiveness

Today

Tomorrow:

molecular

diagnostics

impact

Combine imaging and molecular diagnostics to improve

patient outcomes and save on healthcare costs

GE combines

PET expertise with proprietary imaging agents

•

Fluciclovine:

†

for detecting presence

of tumor metabolic activity

•

Fluciclatide:

†

for measuring tumor

growth

GEHC oncology PET imaging portfolio

Oncology drugs

Sales 2009

Avastin™

(becvacizumab)

$6B

Sutent™

(sunitinib)

$1B

Nexavar™

(sorafenib)

$0.6B

Targeted therapies effective in ‘right patients’

Targeted therapeutics need targeted

diagnostics to be cost-effective

+

Increased accuracy

Therapy monitoring: rapid assessment of patient response

saving costs, improving care

GEHC can deliver an integrated approach

GE Healthcare can combine imaging information for

increased diagnostic confidence

Fluciclatide

†

molecular marker of

therapy response

PET VCAR

precise pre and post –

treatment comparison

In vivo diagnostics to help monitor therapy

Baseline before

treatment

Follow-up: quantitative

proof of drug efficacy

Roche

Pfizer

Bayer

†

Limited by U.S. law to investigational use only

1

2

3

4

Advanced oncology diagnostics services with

broad menu of ~

350

tests to assess &

characterize cancer 

Strong pipeline of 20+ proprietary molecular

diagnostic tests for breast, lung, prostate &

colon cancer

Strong distribution channel with US-wide

coverage …

strong pathology customer base

Integration capabilities for new molecular

diagnostics tests

On-going pharma

biomarker collaborations

5

Strong service operations & distribution channel for proprietary

in vitro content …

scalable & growing at 68% CAGR

In vitro diagnostics help choose therapy

Why Clarient?

Range of products to guide therapy decisions

Strong in vivo and in vitro coverage across oncology & neurology

Molecular diagnostics pipeline

Estimated

Launch

Molecular

Diagnostic

Clinical

relevance

Opportunity

Pulmotype

†

(in vitro)

Lung cancer

therapy choice

Differentiate Lung Cancer.

Integrate GRC technology

for better sample handling

Q1, 2010

Mammostrat

†

(in vitro)

Risk of breast

cancer recurrence

Market primed for tests

driving therapy selection

Q4, 2010

Flutemetamol

†

†

(in vivo PET)

Alzheimer’s

disease marker

Detect and locate amyloid

plaque

2012

Fluciclatide

†

†

(in vivo

PET)

Therapy

monitoring

Measure angiogenesis 

(tumor growth) activity

2013

Taxane

†

(in vitro)

Identify taxane

responders

Utility in lung, breast, ovarian

cancer

2013

†

Assumes completion of the Clarient

transaction

†

†

Limited by U.S. law to investigational use only

GE Healthcare competencies

Investing to become a leader in Molecular Diagnostics

in vivo molecular

imaging

Medical Diagnostics

Digitizing the

pathology

Workflow …

Omnyx™

/HCIT

Multiplexed

signatures, small

samples

Assays, operations &

commercialization

Operations &

commercialization

Molecular imaging

agents & equipment

Technology

& content

Enabling

workflow

in vivo

diagnostics

GRC

Molecular

Pathology

Digital

Pathology

Clarient